Summary:
In adults with type 2 diabetes mellitus, combination therapy with dapagliflozin and exenatide
significantly improved β-cell function and insulin sensitivity compared to dapagliflozin or exenatide monotherapy, though it was associated with gastrointestinal side effects, mainly nausea and diarrhea.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes mellitus inadequately controlled on conventional therapy. |
| Intervention | Combination therapy with dapagliflozin 10 mg daily and exenatide 2 mg once weekly. |
| Comparison | Dapagliflozin 10 mg daily monotherapy or exenatide 2 mg once weekly monotherapy. |
| Outcome | Combination therapy significantly enhanced β-cell function (HOMA2-B) and insulin sensitivity (Matsuda index) compared to either monotherapy. Secondary outcomes included reductions in HbA1c levels and body weight. Main adverse effects were gastrointestinal, such as nausea and diarrhea. |
Source: Triplitt, Curtis, et al. “Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes.” Read article here.
